Organic extract of
Geodia cydonium extract
antiproliferative effect
cell cycle block
mesothelioma
solid-phase extraction
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
05
04
2022
accepted:
23
05
2022
entrez:
11
7
2022
pubmed:
12
7
2022
medline:
12
7
2022
Statut:
epublish
Résumé
The serious side effects caused by chemotherapeutics and the development of cancer chemoresistance represent the most significant limitations in the treatment of cancer. Some alternative approaches have been developed in recent years, which are based on natural compounds, and have allowed important advances in cancer therapeutics. During the last 50 years, sponges have been considered a promising source of natural products from the marine environment, representing ~30% of all marine natural products. Among sponges, the Mediterranean species
Identifiants
pubmed: 35814825
doi: 10.3892/ol.2022.13406
pii: OL-24-02-13406
pmc: PMC9260718
doi:
Types de publication
Journal Article
Langues
eng
Pagination
286Informations de copyright
Copyright: © Di Meo et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Mar Drugs. 2019 Feb 21;17(2):
pubmed: 30795557
Mol Biol Cell. 1995 Apr;6(4):387-400
pubmed: 7626805
Nature. 2004 Nov 18;432(7015):316-23
pubmed: 15549093
J Control Release. 2018 Feb 10;271:139-148
pubmed: 29277680
J Exp Clin Cancer Res. 2019 Aug 16;38(1):360
pubmed: 31419989
Oncogene. 1999 Apr 22;18(16):2557-66
pubmed: 10353599
Int J Mol Sci. 2020 Mar 07;21(5):
pubmed: 32155978
Curr Genomics. 2017 Apr;18(2):106-131
pubmed: 28367072
Oncogene. 2017 Jan 19;36(3):350-361
pubmed: 27270438
Mol Biosyst. 2008 Jun;4(6):622-8
pubmed: 18493661
Sci Rep. 2016 May 31;6:27071
pubmed: 27243769
Front Cell Dev Biol. 2021 Mar 11;9:640972
pubmed: 33777948
Mar Drugs. 2014 Aug 19;12(8):4539-77
pubmed: 25196730
Adv Microb Physiol. 2018;73:171-220
pubmed: 30262109
Int J Mol Sci. 2017 Oct 09;18(10):
pubmed: 28991212
Cancer Med. 2019 Sep;8(12):5662-5672
pubmed: 31364822
BMC Complement Altern Med. 2013 Dec 05;13:344
pubmed: 24305113
Cancers (Basel). 2019 Aug 21;11(9):
pubmed: 31438587
Curr Cancer Drug Targets. 2010 Feb;10(1):19-26
pubmed: 20088796
Mar Environ Res. 2017 Jul;128:58-69
pubmed: 27160988
Mar Drugs. 2019 Aug 23;17(9):
pubmed: 31443597
Recent Pat Anticancer Drug Discov. 2012 May 1;7(2):218-32
pubmed: 22216781
Curr Protein Pept Sci. 2017;18(9):885-904
pubmed: 27455970
Mar Biotechnol (NY). 2005 May-Jun;7(3):142-62
pubmed: 15776313
Br J Cancer. 1999 Jan;79(2):267-77
pubmed: 9888468
Mar Drugs. 2021 Apr 27;19(5):
pubmed: 33925365
Mediators Inflamm. 2015;2015:204975
pubmed: 26491222
Cancer Res. 2020 Sep 1;80(17):3451-3458
pubmed: 32341036
Nat Prod Rep. 2014 Jan 17;31(2):160-258
pubmed: 24389707
J Nat Prod. 2000 Jan;63(1):79-85
pubmed: 10650083
Nat Rev Cancer. 2001 Dec;1(3):222-31
pubmed: 11902577
Patholog Res Int. 2011;2011:605042
pubmed: 22007345
Mar Drugs. 2017 Oct 13;15(10):
pubmed: 29027954
J Antibiot (Tokyo). 2006 Feb;59(2):86-92
pubmed: 16629408
Mar Drugs. 2011;9(10):2131-54
pubmed: 22073013
Oncogene. 2002 Jul 11;21(30):4680-90
pubmed: 12096344
Oncotarget. 2018 May 25;9(40):26259-26278
pubmed: 29899857
Mar Drugs. 2014 Dec 02;12(12):5817-38
pubmed: 25474189
Dev Cell. 2008 Feb;14(2):159-69
pubmed: 18267085
Cell Growth Differ. 1996 Oct;7(10):1283-90
pubmed: 8891332
PLoS One. 2011;6(8):e23569
pubmed: 21858171
Mar Drugs. 2015 Sep 11;13(9):5736-49
pubmed: 26378547
Development. 2013 Aug;140(15):3079-93
pubmed: 23861057
Nat Rev Cancer. 2008 Apr;8(4):253-67
pubmed: 18354415